We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Shielding for Patients with Implanted Devices

By HospiMedica staff writers
Posted on 09 Dec 2002
New shielding technology is designed to protect implanted and interoperative medical devices against interference from the radio frequency (RF) energy emitted by magnetic resonance imaging (MRI). More...
The technology was exhibited at the annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL (USA).

In tests, conducted in a 1.5 Tesla MRI system, the shielding prevented most of the RF energy emitted by the MRI system from reaching the shielded samples, which were coated wafers and metal rods. RF energy from MRI is known to be the cause of dangerously high tissue heating and other performance problems in electronic medical devices used in the body, such as implantable pacemakers, cardioverter-defibrillators, and neurostimulators, as well as guidewires and catheters. A contraindication by the US Food and Drug Administration (FDA) for many of these devices makes it very difficult for patients with the devices to obtain an MRI exam.

The new technology uses thin-film nanomagnetic and carbon composite coatings and novel shield designs, which can be used individually or together to meet the specific shielding requirements of a range of medical devices. The next tests will be performed on coated pacemaker leads in a saline solution phantom to approximate the effects of a human body in an MRI coil. The shielding was developed by Biophan Technologies (Rochester, NY, USA).

"The ability of manufacturers of pacemakers and other devices to apply the Biophan technologies with minimal disruption to existing products and their manufacturing processes could also significantly reduce time to market and capital requirements,” said Michael Weiner, CEO of Biophan.




Related Links:
Biophan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.